Comparison of 2 alternative antiretroviral combinations in HIV post-exposure prophylaxis: AZT-3TC [lamivudine/zidovudine] (Combivir) + lopinavir-ritonavir (Kaletra) versus AZT-3TC (Combivir)+ atazanavir (Reyataz). Multicentre, prospective, randomized, open study

Trial Profile

Comparison of 2 alternative antiretroviral combinations in HIV post-exposure prophylaxis: AZT-3TC [lamivudine/zidovudine] (Combivir) + lopinavir-ritonavir (Kaletra) versus AZT-3TC (Combivir)+ atazanavir (Reyataz). Multicentre, prospective, randomized, open study

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Atazanavir (Primary) ; Lopinavir/ritonavir (Primary) ; Lamivudine/zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top